China’s Sinocap vaccine, developed by China National Pharmaceutical Group, is in Phase III clinical trials in Peru, and local media are reporting that it is only 11.5 percent effective, dealing a blow to the Chinese Communist Party, which is pursuing vaccine diplomacy. In addition, domestic media confirmed that they received a stern warning not to reproduce any negative information about the domestically produced New Crown (CCP virus) vaccine.
Peruvian media revealed last week that the Phase III clinical trial results of the New Crown vaccine developed by the Wuhan Institute of Biological Products of Sinopharm, a Chinese pharmaceutical group, in Peru showed a 33 percent effectiveness rate, while the New Crown vaccine developed by Sinopharm’s Beijing Institute of Biological Products was only 11.5 percent effective. This is not only much lower than the 80% efficiency rate previously announced by the Chinese Communist Party, but also much lower than the 50% efficiency rate generally set by the World health Organization and regulatory agencies in various countries as the threshold for vaccine compliance.
A central media reporter revealed that any negative news related to vaccines is very sensitive because Beijing is pushing vaccine diplomacy in third world countries. Domestic media have been warned not to report any negative information about domestic vaccines.
Ms. Zhu, a front-line worker in China’s Epidemic prevention, pointed out to the station that it is almost an open secret that the effectiveness of domestic vaccines is being questioned, only that no one can say anything. Even within China’s CDC system, half of the population refuses to receive the domestic New Crown vaccine. She reminded that older people or those with underlying diseases are not recommended to receive the domestic vaccine.
Miss Zhu said: older people are advised not to fight, no underlying disease is still better, with underlying disease, it is not recommended to fight. And you see the CDC, half of them did not play. There is no parameter to refer to. And it seems to be valid for a few months, it is not a lifetime, half a year later it will expire, there is no point. It is quite a tangle, this problem. The doctor, in fact, also let you make your own decision, he will not say you can play or not to play. It’s a psychological comfort, I’ll tell you.
The former head of the Chinese Red Cross major medical aid project, Ren Ruihong, pointed out that the clinical information of the national drug vaccine has not been made public so far, and now the foreign media has revealed that the phase III clinical trial information shows poor utility. But she said this is entirely expected. She said that the effectiveness of the domestic vaccine itself is doubtful, coupled with its inactivated vaccine is developed with the earliest strains, with a large number of virus variants, its effect itself will be rapidly weakened.
Ren Ruihong said: Inactivated vaccines are now the most done in China, made with the very first strains. So it is basically no resistance to this variant of the virus. The efficiency of this has always been a very controversial issue, but its efficiency is very low, this is known to everyone. The latest study says that Pfizer’s, if it has a variant, it is slightly adjusted, and then the third or fourth injection, can completely resist the variant of the virus. But like inactivated, including adenovirus vaccines, the protection against this variant of the virus will be significantly reduced.
Sinopharm issued a statement on Saturday (6), saying that the Peruvian media had been misinformed and that it would reserve the right to pursue responsibility.
Our reporter called Sinopharm several times, but the organization’s phone number has been unavailable.
The Peruvian Ministry of Health, on the other hand, defended Sinopharm, repeating that Communist Party officials had previously announced that the trial in the United Arab Emirates had obtained 79.34 percent efficiency. However, Peruvian authorities have never released information on the vaccine’s trials in Peru.
Since the outbreak and spread of the New Crown epidemic in Wuhan early last year, Chinese Communist Party officials have been engaged in a national race for a New Crown vaccine. But with the successful development of vaccines in advanced countries and China’s own short supply of vaccines, the Chinese government is once again pushing vaccine diplomacy, but at high cost and with little success.
Recent Comments